152 related articles for article (PubMed ID: 30194485)
21. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
22. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
23. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
[TBL] [Abstract][Full Text] [Related]
25. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations.
Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T
Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087
[TBL] [Abstract][Full Text] [Related]
26. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.
Wang J; He P; Gaida M; Yang S; Schetter AJ; Gaedcke J; Ghadimi BM; Ried T; Yfantis H; Lee D; Weiss JM; Stauffer J; Hanna N; Alexander HR; Hussain SP
Oncotarget; 2016 Aug; 7(33):52993-53004. PubMed ID: 27367029
[TBL] [Abstract][Full Text] [Related]
27. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
28. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
[TBL] [Abstract][Full Text] [Related]
29. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
30. Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.
Soliman AS; Bondy M; Webb CR; Schottenfeld D; Bonner J; El-Ghawalby N; Soultan A; Abdel-Wahab M; Fathy O; Ebidi G; Zhang Q; Greenson JK; Abbruzzese JL; Hamilton SR
Int J Cancer; 2006 Sep; 119(6):1455-61. PubMed ID: 16619252
[TBL] [Abstract][Full Text] [Related]
31. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
32. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine.
Hansen MF; Johansen J; Bjørnevoll I; Sylvander AE; Steinsbekk KS; Sætrom P; Sandvik AK; Drabløs F; Sjursen W
Fam Cancer; 2015 Sep; 14(3):437-48. PubMed ID: 25860647
[TBL] [Abstract][Full Text] [Related]
33. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.
Dal Molin M; Zhang M; de Wilde RF; Ottenhof NA; Rezaee N; Wolfgang CL; Blackford A; Vogelstein B; Kinzler KW; Papadopoulos N; Hruban RH; Maitra A; Wood LD
Clin Cancer Res; 2015 Apr; 21(8):1944-50. PubMed ID: 25623214
[TBL] [Abstract][Full Text] [Related]
34. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas.
Spier I; Holzapfel S; Altmüller J; Zhao B; Horpaopan S; Vogt S; Chen S; Morak M; Raeder S; Kayser K; Stienen D; Adam R; Nürnberg P; Plotz G; Holinski-Feder E; Lifton RP; Thiele H; Hoffmann P; Steinke V; Aretz S
Int J Cancer; 2015 Jul; 137(2):320-31. PubMed ID: 25529843
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
36. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
Zhu Z; Xu Y; Du J; Tan J; Jiao H
J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Molecular Characterization of
Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
